BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 2019;94:635-40. [PMID: 30859608 DOI: 10.1002/ajh.25459] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Sorigue M, Cañamero E, Siguenza P, Nomdedeu M, López-núñez JJ. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leukemia & Lymphoma 2020;61:1277-91. [DOI: 10.1080/10428194.2020.1713321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nicol M, Siguret V, Vergaro G, Aimo A, Emdin M, Dillinger JG, Baudet M, Cohen-Solal A, Villesuzanne C, Harel S, Royer B, Arnulf B, Logeart D. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail 2021. [PMID: 34784656 DOI: 10.1002/ehf2.13701] [Reference Citation Analysis]
3 Barrett A, Quinn J, Lavin M, Thornton P, O'Donnell J, Murphy P, Glavey S. Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. J Clin Med 2021;10:3536. [PMID: 34441832 DOI: 10.3390/jcm10163536] [Reference Citation Analysis]
4 Santoro M, Romano A, Mancuso S, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Med 2021;63:1-6. [PMID: 32955183 DOI: 10.23736/S0031-0808.20.04133-6] [Reference Citation Analysis]
5 Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:555-61. [PMID: 32314352 DOI: 10.1111/bjh.16653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Maraveyas A. Latest advances in preventing thromboembolic disease in the ambulatory oncology patient. Thromb Res 2020;191 Suppl 1:S91-8. [PMID: 32736786 DOI: 10.1016/S0049-3848(20)30404-7] [Reference Citation Analysis]
7 Merz AMA, Merz M, Hillengass J, Holstein SA, Mccarthy P. The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy 2019;19:889-98. [DOI: 10.1080/14737140.2019.1674142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 LeBlanc R, Bergstrom DJ, Côté J, Kotb R, Louzada ML, Sutherland HJ. Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00311-6. [PMID: 34456159 DOI: 10.1016/j.clml.2021.07.028] [Reference Citation Analysis]
9 Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G, Tibullo D, Di Raimondo F, Signorelli SS. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. J Clin Med 2020;9:E2876. [PMID: 32899553 DOI: 10.3390/jcm9092876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Pozzi S, Bari A, Pecherstorfer M, Vallet S. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel) 2021;13:4978. [PMID: 34638462 DOI: 10.3390/cancers13194978] [Reference Citation Analysis]
11 Savvari P. Cancer-associated thromboembolism: could direct-acting oral anticoagulants be a promising therapeutic option? Literature review. Forum of Clinical Oncology 2020;11:22-8. [DOI: 10.2478/fco-2019-0009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F, Garcia AVM, Angelini DE, Mazzoni S, Faiman B, Valent J, Khouri J. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 2021;193:1213-9. [PMID: 33997961 DOI: 10.1111/bjh.17505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Leclerc V, Karlin L, Herledan C, Marchal L, Baudouin A, Gouraud A, Caffin AG, Larbre V, Lazareth A, Bachy E, Salles G, Ghesquières H, Rioufol C, Ranchon F. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. J Cancer Res Clin Oncol 2021. [PMID: 34143239 DOI: 10.1007/s00432-021-03693-5] [Reference Citation Analysis]
14 Kahale LA, Matar CF, Tsolakian I, Hakoum MB, Yosuico VE, Terrenato I, Sperati F, Barba M, Hicks LK, Schünemann H, Akl EA. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database Syst Rev 2021;9:CD014739. [PMID: 34582035 DOI: 10.1002/14651858.CD014739] [Reference Citation Analysis]
15 Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk 2021;21:188-198.e2. [PMID: 33339769 DOI: 10.1016/j.clml.2020.11.015] [Reference Citation Analysis]
16 Gonzalez-Porras JR, Mateo J, Gonzalez-Calle V, Marco P, Garcia-Gutierrez V, Reverter JC, Lecumberri R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clin Transl Oncol 2021. [PMID: 34850351 DOI: 10.1007/s12094-021-02735-1] [Reference Citation Analysis]
17 Vekemans MC, Doyen C, Caers J, Wu K, Kentos A, Mineur P, Michaux L, Delforge M, Meuleman N. Recommendations on the management of multiple myeloma in 2020. Acta Clin Belg 2022;77:445-61. [PMID: 33355041 DOI: 10.1080/17843286.2020.1860411] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020;136:1091-104. [PMID: 32438407 DOI: 10.1182/blood.2020005125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
19 Fotiou D, Gavriatopoulou M, Terpos E. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel) 2020;12:E191. [PMID: 31940972 DOI: 10.3390/cancers12010191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
20 Wang TF, Billett HH, Connors JM, Soff GA. Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. Oncologist 2021;26:e17-23. [PMID: 33275323 DOI: 10.1002/onco.13570] [Reference Citation Analysis]
21 Sayar Z, Gates C, Bristogiannis S, Patel A, Ogunbiyi MO, Tailor A, Yong K, Thomas M. Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.03.001] [Reference Citation Analysis]
22 Itzhaki Ben Zadok O, Kornowski R. Cardiac Care of Patients with Cardiac Amyloidosis. Acta Haematol 2020;143:343-51. [PMID: 32408301 DOI: 10.1159/000506919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Smythe MA, Burns C, Liu Q, Garwood CL. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? Ann Pharmacother 2021;:10600280211025042. [PMID: 34137279 DOI: 10.1177/10600280211025042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Berbari HE, Kumar SK. Initial Therapeutic Approaches to Patients with Multiple Myeloma. Adv Ther 2021;38:3694-711. [PMID: 34145483 DOI: 10.1007/s12325-021-01824-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]